A recently published Phase 1/2 study investigated CD19-directed CAR-NK cells in 11 heavily pretreated patients with lymphoma and reported overall response rate of 73% (8/11 patients), with 88% of patients still being negative for MRD after 30 days from infusions at all dose levels [15]. This evidence concerns the gene CD19 and lymphoma.